Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Zentalis to host R&D day on December 16 » 07:13
12/02/21
12/02
07:13
12/02/21
07:13
ZNTL

Zentalis

$73.56 /

-8.6 (-10.47%)

Zentalis Pharmaceuticals…

Zentalis Pharmaceuticals is hosting a virtual R&D Day on December 16, 2021 from 11:00 a.m. to 12:00 p.m. EST. Zentalis' management team along with three Key Opinion Leaders will present preclinical science from multiple programs and clinical updates on ZN-d5, the Company's oral, selective BCL-2 inhibitor for hematologic malignancies, and ZN-e4, the Company's oral EGFR inhibitor for non-small cell lung carcinoma.

ShowHide Related Items >><<
ZNTL Zentalis
$73.56 /

-8.6 (-10.47%)

ZNTL Zentalis
$73.56 /

-8.6 (-10.47%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$73.56 /

-8.6 (-10.47%)

  • 29
    Jun
Over a week ago
Conference/Events
Jefferies to hold a virtual conference » 04:55
11/18/21
11/18
04:55
11/18/21
04:55
ALXO

ALX Oncology

$42.93 /

-2.02 (-4.49%)

, GLTO

Galecto

$3.05 /

-0.13 (-4.09%)

, NBTX

Nanobiotix

$9.35 /

-0.2 (-2.09%)

, EXAS

Exact Sciences

$88.36 /

-3.12 (-3.41%)

, RXDX

Prometheus

$38.32 /

+2.32 (+6.44%)

, ARWR

Arrowhead

$63.75 /

-0.07 (-0.11%)

, PNT

Point Biopharma

$8.90 /

-0.13 (-1.44%)

, CNCE

Concert Pharmaceuticals

$3.99 /

-0.08 (-1.97%)

, AFMD

Affimed

$6.73 /

+0.605 (+9.88%)

, EPIX

Essa Pharma

$13.00 /

-0.31 (-2.33%)

, GRTX

Galera Therapeutics

$1.69 /

+0.015 (+0.90%)

, INAB

In8bio

$8.05 /

+ (+0.00%)

, KROS

Keros Therapeutics

$60.31 /

-2.51 (-4.00%)

, LABP

Landos Biopharma

$10.17 /

-0.55 (-5.13%)

, SVRA

Savara

$1.12 /

-0.005 (-0.45%)

, STRO

Sutro Biopharma

$18.47 /

-0.57 (-2.99%)

, VACC

Vaccitech

$12.70 /

+0.01 (+0.08%)

, ZNTL

Zentalis

$79.38 /

+2.39 (+3.10%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

INAB In8bio
$8.05 /

+ (+0.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.05 /

-0.13 (-4.09%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.73 /

+0.605 (+9.88%)

11/17/21 Berenberg
Affimed initiated with a Buy at Berenberg
10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.05 /

+ (+0.00%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.005 (-0.45%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

11/17/21 Berenberg
Sutro Biopharma initiated with a Buy at Berenberg
06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

INAB In8bio
$8.05 /

+ (+0.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

Hot Stocks
Zentalis announces fast track designation granted by FDA to ZN-c3 » 07:03
11/17/21
11/17
07:03
11/17/21
07:03
ZNTL

Zentalis

$76.99 /

-0.11 (-0.14%)

Zentalis Pharmaceuticals…

Zentalis Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to ZN-c3, the Company's oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma, USC, in adult women. "USC is a devastating endometrial cancer marked by low survival rates and high rates of recurrence. Receiving Fast Track designation for ZN-c3 is an important milestone, as it underscores the need for novel, effective treatment options for this aggressive and often fatal disease," commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis. "ZN-c3, our potentially first- and best-in-class oral WEE1 inhibitor, is a notable clinical advancement in DNA damage response and synthetic lethality and is currently being evaluated in a potentially registrational Phase 2 trial in USC. We are grateful for the opportunity to have more frequent interactions with the FDA as we continue to quickly advance the development of this promising candidate for patients in need."

ShowHide Related Items >><<
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

  • 29
    Jun
Conference/Events
Jefferies to hold a virtual conference » 04:55
11/17/21
11/17
04:55
11/17/21
04:55
ALXO

ALX Oncology

$45.00 /

-1.185 (-2.57%)

, GLTO

Galecto

$3.18 /

-0.33 (-9.40%)

, NBTX

Nanobiotix

$9.50 /

+ (+0.00%)

, EXAS

Exact Sciences

$91.45 /

+1.56 (+1.74%)

, RXDX

Prometheus

$36.15 /

+1.75 (+5.09%)

, ARWR

Arrowhead

$63.96 /

-1.98 (-3.00%)

, PNT

Point Biopharma

$9.02 /

+0.17 (+1.92%)

, CNCE

Concert Pharmaceuticals

$4.07 /

+0.06 (+1.50%)

, AFMD

Affimed

$6.13 /

+0.095 (+1.57%)

, EPIX

Essa Pharma

$13.37 /

+0.4 (+3.08%)

, GRTX

Galera Therapeutics

$1.68 /

+0.005 (+0.30%)

, INAB

In8bio

$8.05 /

-0.13 (-1.59%)

, KROS

Keros Therapeutics

$62.90 /

+1.4 (+2.28%)

, LABP

Landos Biopharma

$10.65 /

-3.35 (-23.93%)

, SVRA

Savara

$1.12 /

-0.015 (-1.32%)

, STRO

Sutro Biopharma

$19.06 /

-0.04 (-0.21%)

, VACC

Vaccitech

$12.65 /

-0.17 (-1.33%)

, ZNTL

Zentalis

$76.99 /

-0.11 (-0.14%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

INAB In8bio
$8.05 /

-0.13 (-1.59%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.18 /

-0.33 (-9.40%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.50 /

+ (+0.00%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.13 /

+0.095 (+1.57%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.05 /

-0.13 (-1.59%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.015 (-1.32%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

INAB In8bio
$8.05 /

-0.13 (-1.59%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

Conference/Events
Jefferies to hold a virtual conference » 10:32
11/16/21
11/16
10:32
11/16/21
10:32
ALXO

ALX Oncology

$44.59 /

-1.59 (-3.44%)

, GLTO

Galecto

$3.48 /

-0.03 (-0.85%)

, NBTX

Nanobiotix

$9.50 /

+ (+0.00%)

, EXAS

Exact Sciences

$88.17 /

-1.72 (-1.91%)

, RXDX

Prometheus

$34.65 /

+0.25 (+0.73%)

, ARWR

Arrowhead

$64.90 /

-1.04 (-1.58%)

, PNT

Point Biopharma

$8.86 /

+0.01 (+0.11%)

, CNCE

Concert Pharmaceuticals

$3.95 /

-0.06 (-1.50%)

, AFMD

Affimed

$6.03 /

-0.005 (-0.08%)

, EPIX

Essa Pharma

$14.02 /

+1.05 (+8.10%)

, GRTX

Galera Therapeutics

$1.64 /

-0.03 (-1.80%)

, INAB

In8bio

$8.46 /

+0.28 (+3.42%)

, KROS

Keros Therapeutics

$62.28 /

+0.78 (+1.27%)

, LABP

Landos Biopharma

$12.89 /

-1.11 (-7.93%)

, SVRA

Savara

$1.12 /

-0.015 (-1.32%)

, STRO

Sutro Biopharma

$19.16 /

+0.06 (+0.31%)

, VACC

Vaccitech

$12.76 /

-0.06 (-0.47%)

, ZNTL

Zentalis

$77.86 /

+0.755 (+0.98%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

INAB In8bio
$8.46 /

+0.28 (+3.42%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.48 /

-0.03 (-0.85%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.50 /

+ (+0.00%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.03 /

-0.005 (-0.08%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.46 /

+0.28 (+3.42%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.015 (-1.32%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

INAB In8bio
$8.46 /

+0.28 (+3.42%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

Recommendations
Zentalis price target raised to $120 from $80 at H.C. Wainwright » 06:17
11/11/21
11/11
06:17
11/11/21
06:17
ZNTL

Zentalis

$78.41 /

+0.485 (+0.62%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Zentalis Pharmaceuticals to $120 from $80 and keeps a Buy rating on the shares. The analyst is including ZN-c3 into his valuation based on its ability to overcome the limitations seen with fulvestrant. While novel oncology targets have met with mixed results, the preclinical and clinical body of evidence is supportive of ZN-c3's efficacy in multiple indications including uterine serous carcinoma, osteosarcoma, ovarian cancer and additional solid tumors, "which remain very compelling," Fein tells investors in a research note.

ShowHide Related Items >><<
ZNTL Zentalis
$78.41 /

+0.485 (+0.62%)

ZNTL Zentalis
$78.41 /

+0.485 (+0.62%)

10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
10/06/21 Jefferies
Zentalis assumed with a Buy at Jefferies
ZNTL Zentalis
$78.41 /

+0.485 (+0.62%)

  • 29
    Jun
Hot Stocks
Zentalis expects cash to fund requirements into 3Q23 » 07:13
11/10/21
11/10
07:13
11/10/21
07:13
ZNTL

Zentalis

$78.21 /

-1.03 (-1.30%)

As of September 30, 2021,…

As of September 30, 2021, Zentalis had cash, cash equivalents and marketable securities of $366.8 million. We believe that our existing cash, cash equivalents and marketable securities as of September 30, 2021 will be sufficient to fund our operating expenses and capital expenditures requirements into the third quarter of 2023.

ShowHide Related Items >><<
ZNTL Zentalis
$78.21 /

-1.03 (-1.30%)

ZNTL Zentalis
$78.21 /

-1.03 (-1.30%)

10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
10/06/21 Jefferies
Zentalis assumed with a Buy at Jefferies
ZNTL Zentalis
$78.21 /

-1.03 (-1.30%)

  • 29
    Jun
Earnings
Zentalis reports Q3 EPS (9c), consensus ($1.31) » 07:13
11/10/21
11/10
07:13
11/10/21
07:13
ZNTL

Zentalis

/

+

"This past quarter,…

"This past quarter, Zentalis continued to execute on its clinical development strategy, and we are pleased with the progress we have made to advance our lead program, ZN-c3, a potentially best-in-class WEE1 inhibitor," commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis. "Most recently, we initiated a Phase 1/2 trial with ZN-c3 in combination with gemcitabine in patients with osteosarcoma, further supporting the broad potential of ZN-c3 in combination therapy settings. Before year-end, we plan to have a total of six ongoing trials investigating our WEE1 inhibitor and look forward to initiating our potentially registrational biomarker-driven Phase 2 trial shortly. Additionally, the foundational research on the discovery of ZN-c3 was published in the peer-reviewed Journal of Medicinal Chemistry, which reviews our objectives for designing ZN-c3 as a potentially safer and more selective WEE1 inhibitor and in turn, overcoming limitations seen with other candidates in development. We remain on track with our anticipated clinical milestones and are eager to provide future updates on these efforts. Looking ahead, we are excited to host a virtual R&D Day on December 16, during which our management team and key opinion leaders will provide a review of new preclinical science across multiple programs and share clinical updates on ZN-d5 and ZN-e4."

ShowHide Related Items >><<
ZNTL Zentalis
/

+

ZNTL Zentalis
/

+

10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
10/06/21 Jefferies
Zentalis assumed with a Buy at Jefferies
ZNTL Zentalis
/

+

  • 29
    Jun
Over a month ago
Recommendations
Zentalis price target raised to $84 from $64 at SVB Leerink » 09:33
10/28/21
10/28
09:33
10/28/21
09:33
ZNTL

Zentalis

$76.76 /

-2.74 (-3.45%)

SVB Leerink analyst…

SVB Leerink analyst Andrew Berens raised the firm's price target on Zentalis to $84 from $64 and keeps an Outperform rating on the shares. Going into Q3 earnings, the analyst believes that ZN-c3 continues to be a key focus for investors. Berens is also increasing his probability of success for ZN-c3 from 35% to 60%, particularly given the asset's differentiated safety profile over adavosertib, which should enable a clinical advantage.

ShowHide Related Items >><<
ZNTL Zentalis
$76.76 /

-2.74 (-3.45%)

ZNTL Zentalis
$76.76 /

-2.74 (-3.45%)

10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
10/06/21 Jefferies
Zentalis assumed with a Buy at Jefferies
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
ZNTL Zentalis
$76.76 /

-2.74 (-3.45%)

  • 29
    Jun
Recommendations
Zentalis price target raised to $89 from $65 at Wedbush » 09:05
10/27/21
10/27
09:05
10/27/21
09:05
ZNTL

Zentalis

$79.01 /

+0.75 (+0.96%)

Wedbush analyst Robert…

Wedbush analyst Robert Driscoll raised the firm's price target on Zentalis to $89 from $65 in light of additional recent validating clinical data for targeting Wee1, as he incorporates broader opportunities into his model that reflect clinical development progress for the company's Wee1 inhibitor ZN-c3. The analyst keeps an Outperform rating on the shares.

ShowHide Related Items >><<
ZNTL Zentalis
$79.01 /

+0.75 (+0.96%)

ZNTL Zentalis
$79.01 /

+0.75 (+0.96%)

10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
10/06/21 Jefferies
Zentalis assumed with a Buy at Jefferies
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
09/28/21 Oppenheimer
Zentalis initiated with an Outperform at Oppenheimer
ZNTL Zentalis
$79.01 /

+0.75 (+0.96%)

  • 29
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.